{"id":78735,"date":"2026-09-04T15:33:04","date_gmt":"2026-09-04T07:33:04","guid":{"rendered":"https:\/\/flcube.com\/?p=78735"},"modified":"2026-09-04T15:33:05","modified_gmt":"2026-09-04T07:33:05","slug":"ganlees-gzc8072-wins-nmpa-ind-approval-for-once-weekly-oral-type-2-diabetes-candidate","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=78735","title":{"rendered":"GanLee\u2019s GZC8072 Wins NMPA IND Approval for Once\u2011Weekly Oral Type 2 Diabetes Candidate"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Gan &amp; Lee Pharmaceuticals (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/603087:SHA\">SHA: 603087<\/a>)<\/strong> announced that its drug candidate <strong>GZC8072<\/strong> has received <strong>Investigational New Drug (IND) approval<\/strong> from <strong>China\u2019s National Medical Products Administration (NMPA)<\/strong> for the treatment of <strong>type 2 diabetes<\/strong>. The clearance marks a key regulatory step for the company\u2019s next-generation, ultra-long-acting <strong>oral weekly peptide<\/strong>, a molecule class for which no approved therapy currently exists worldwide.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Agency<\/td><td><strong>National Medical Products Administration (NMPA)<\/strong>, China<\/td><\/tr><tr><td>Approval Type<\/td><td>Investigational New Drug (IND)<\/td><\/tr><tr><td>Product<\/td><td><strong>GZC8072<\/strong><\/td><\/tr><tr><td>Indication<\/td><td><strong>Type 2 diabetes<\/strong><\/td><\/tr><tr><td>Date<\/td><td>04 Sept 2026<\/td><\/tr><tr><td>Next Steps<\/td><td>Initiation of clinical development program in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>GZC8072<\/strong>, a next-generation biased, ultra-long-acting oral weekly peptide independently developed by <strong>Gan &amp; Lee Pharmaceuticals<\/strong><\/li>\n\n\n\n<li><strong>Therapeutic Class:<\/strong> Oral GLP-1-class peptide candidate for <strong>type 2 diabetes<\/strong>, designed to support a once-weekly oral dosing regimen<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Biased agonism combined with extended half-life engineering to enhance potency and durability of effect<\/li>\n\n\n\n<li><strong>Platform Technology:<\/strong> Built on the company\u2019s proprietary <strong>NovaPeptide<\/strong> and <strong>SupOraTide<\/strong> platforms<\/li>\n\n\n\n<li><strong>Bioavailability:<\/strong> Significantly improved oral bioavailability versus conventional peptide formulations \u2014 a core differentiator for oral weekly dosing<\/li>\n\n\n\n<li><strong>IP Position:<\/strong> Independently developed molecule leveraging in-house platform technologies<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-development-status-amp-clinical-outlook\" class=\"wp-block-heading\">Development Status &amp; Clinical Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>GZC8072 has cleared the IND stage; clinical trials are the next phase of development<\/li>\n\n\n\n<li>As of the announcement\u2019s disclosure date, <strong>no oral weekly GLP-1 tablet has been approved globally for type 2 diabetes<\/strong>, placing the candidate in an emerging and highly competitive category<\/li>\n\n\n\n<li>The once-weekly oral regimen, if validated in clinical studies, would offer a meaningful convenience advantage over daily oral and injectable GLP-1 therapies<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-mover opportunity:<\/strong> The global absence of an approved oral weekly GLP-1 tablet for <strong>type 2 diabetes<\/strong> creates a significant white space that <strong>GZC8072<\/strong> is positioned to address<\/li>\n\n\n\n<li><strong>Platform validation:<\/strong> IND approval provides early regulatory validation of Gan &amp; Lee\u2019s <strong>NovaPeptide<\/strong> and <strong>SupOraTide<\/strong> discovery platforms<\/li>\n\n\n\n<li><strong>Competitive positioning:<\/strong> Ultra-long-acting, once-weekly oral dosing could differentiate the candidate against established daily oral and weekly injectable GLP-1 therapies on convenience and adherence<\/li>\n\n\n\n<li><strong>Pipeline momentum:<\/strong> Strengthens <strong>Gan &amp; Lee Pharmaceuticals\u2019<\/strong> transition beyond its insulin franchise into next-generation incretin-based therapies<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements:<\/strong> This brief is for informational purposes only and does not constitute investment advice or an offer to buy or sell any security. Statements regarding drug development, regulatory approval and market potential are forward-looking and subject to risks and uncertainties, including clinical outcomes, regulatory decisions and competitive developments. Actual results may differ materially. Readers should conduct their own due diligence before making investment decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/603087_20260904_L2OE.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 603087_20260904_L2OE.\"><\/object><a id=\"wp-block-file--media-3cf5e407-4546-45cd-ba3b-d0bfc4b7f86b\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/603087_20260904_L2OE.pdf\">603087_20260904_L2OE<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/603087_20260904_L2OE.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-3cf5e407-4546-45cd-ba3b-d0bfc4b7f86b\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Gan &amp; Lee Pharmaceuticals (SHA: 603087) announced that its drug candidate GZC8072 has received Investigational&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,39,421,1120],"class_list":["post-78735","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-diabetes","tag-gan-lee-pharmaceuticals","tag-sha-603087"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GanLee\u2019s GZC8072 Wins NMPA IND Approval for Once\u2011Weekly Oral Type 2 Diabetes Candidate - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Gan &amp; Lee Pharmaceuticals (SHA: 603087) announced that its drug candidate GZC8072 has received Investigational New Drug (IND) approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of type 2 diabetes. The clearance marks a key regulatory step for the company\u2019s next-generation, ultra-long-acting oral weekly peptide, a molecule class for which no approved therapy currently exists worldwide.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=78735\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GanLee\u2019s GZC8072 Wins NMPA IND Approval for Once\u2011Weekly Oral Type 2 Diabetes Candidate\" \/>\n<meta property=\"og:description\" content=\"Gan &amp; Lee Pharmaceuticals (SHA: 603087) announced that its drug candidate GZC8072 has received Investigational New Drug (IND) approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of type 2 diabetes. The clearance marks a key regulatory step for the company\u2019s next-generation, ultra-long-acting oral weekly peptide, a molecule class for which no approved therapy currently exists worldwide.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=78735\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-04T07:33:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-04T07:33:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78735#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78735\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GanLee\u2019s GZC8072 Wins NMPA IND Approval for Once\u2011Weekly Oral Type 2 Diabetes Candidate\",\"datePublished\":\"2026-09-04T07:33:04+00:00\",\"dateModified\":\"2026-09-04T07:33:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78735\"},\"wordCount\":428,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Diabetes\",\"Gan &amp; Lee Pharmaceuticals\",\"SHA: 603087\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78735#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78735\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=78735\",\"name\":\"GanLee\u2019s GZC8072 Wins NMPA IND Approval for Once\u2011Weekly Oral Type 2 Diabetes Candidate - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-09-04T07:33:04+00:00\",\"dateModified\":\"2026-09-04T07:33:05+00:00\",\"description\":\"Gan & Lee Pharmaceuticals (SHA: 603087) announced that its drug candidate GZC8072 has received Investigational New Drug (IND) approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of type 2 diabetes. The clearance marks a key regulatory step for the company\u2019s next-generation, ultra-long-acting oral weekly peptide, a molecule class for which no approved therapy currently exists worldwide.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78735#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78735\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78735#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GanLee\u2019s GZC8072 Wins NMPA IND Approval for Once\u2011Weekly Oral Type 2 Diabetes Candidate\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GanLee\u2019s GZC8072 Wins NMPA IND Approval for Once\u2011Weekly Oral Type 2 Diabetes Candidate - Insight, China&#039;s Pharmaceutical Industry","description":"Gan & Lee Pharmaceuticals (SHA: 603087) announced that its drug candidate GZC8072 has received Investigational New Drug (IND) approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of type 2 diabetes. The clearance marks a key regulatory step for the company\u2019s next-generation, ultra-long-acting oral weekly peptide, a molecule class for which no approved therapy currently exists worldwide.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=78735","og_locale":"en_US","og_type":"article","og_title":"GanLee\u2019s GZC8072 Wins NMPA IND Approval for Once\u2011Weekly Oral Type 2 Diabetes Candidate","og_description":"Gan & Lee Pharmaceuticals (SHA: 603087) announced that its drug candidate GZC8072 has received Investigational New Drug (IND) approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of type 2 diabetes. The clearance marks a key regulatory step for the company\u2019s next-generation, ultra-long-acting oral weekly peptide, a molecule class for which no approved therapy currently exists worldwide.","og_url":"https:\/\/flcube.com\/?p=78735","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-04T07:33:04+00:00","article_modified_time":"2026-09-04T07:33:05+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=78735#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=78735"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GanLee\u2019s GZC8072 Wins NMPA IND Approval for Once\u2011Weekly Oral Type 2 Diabetes Candidate","datePublished":"2026-09-04T07:33:04+00:00","dateModified":"2026-09-04T07:33:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=78735"},"wordCount":428,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Diabetes","Gan &amp; Lee Pharmaceuticals","SHA: 603087"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=78735#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=78735","url":"https:\/\/flcube.com\/?p=78735","name":"GanLee\u2019s GZC8072 Wins NMPA IND Approval for Once\u2011Weekly Oral Type 2 Diabetes Candidate - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-09-04T07:33:04+00:00","dateModified":"2026-09-04T07:33:05+00:00","description":"Gan & Lee Pharmaceuticals (SHA: 603087) announced that its drug candidate GZC8072 has received Investigational New Drug (IND) approval from China\u2019s National Medical Products Administration (NMPA) for the treatment of type 2 diabetes. The clearance marks a key regulatory step for the company\u2019s next-generation, ultra-long-acting oral weekly peptide, a molecule class for which no approved therapy currently exists worldwide.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=78735#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=78735"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=78735#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GanLee\u2019s GZC8072 Wins NMPA IND Approval for Once\u2011Weekly Oral Type 2 Diabetes Candidate"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=78735"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78735\/revisions"}],"predecessor-version":[{"id":78737,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78735\/revisions\/78737"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=78735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=78735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=78735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}